BioMed Research International / 2017 / Article / Tab 2 / Research Article
Diagnostics of Thyroid Malignancy and Indications for Surgery in the Elderly and Younger Counterparts: Comparison of 3,749 Patients Table 2 Distribution of cases according to gender and age parameters. Data were presented as number (percent).
Female Male <45 years ( ) 45–<65 years ( ) 65 years ( ) value<45 years ( ) 45–<65 years ( ) 65 years ( ) valueCytological diagnosis according to TBSRTC Stage II (normotype thyrocytes, lymphocytes, thyroiditis suspicion) 841 (84.5) 1,382 (87.3) 448 (78.7) 151 (84.8) 261 (91.6) 123 (89.1) 0.254 Stage III (AUS/FLUS) 26 (2.6) 34 (2.2) 13 (2.3) 5 (2.8) 4 (1.4) 2 (1.5) Stage IV (follicular neoplasm) 65 (6.5) 87 (5.5) 50 (8.8) 12 (6.7) 8 (2.8) 3 (2.2) Stage V (malignancy suspicion) 3 (0.3) 15 (1.0) 21 (3.7) 3 (1.7) 2 (0.7) 4 (2.9) Stage V (malignancy/lymphoma suspicion) 0 (0.0) 0 (0.0) 2 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) Stage VI (papillary carcinoma) 59 (5.9) 62 (3.9) 34 (6.0) 7 (3.9) 10 (3.5) 6 (4.4) Stage VI (medullary carcinoma) 1 (0.1) 4 (0.3) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) Clinical suspicion of malignancy No 867 (87.1) 1,416 (89.4) 461 (81.0) 156 (87.6) 265 (93.0) 125 (90.6) 0.157 Yes 128 (12.9) 168 (10.6) 108 (19.0) 22 (12.4) 20 (7.0) 13 (9.4) Indication for surgery (out of malignancy) Trachea compression 278 (32.1) 720 (50.9) 444 (96.3) 46 (30.0) 117 (43.8) 112 (89.6) Recent tumor/goiter enlargement 205 (23.6) 284 (20) 8 (1.7) 79 (50.0) 49 (18.8) 7 (5.6) Urgent indication (acute respiratory failure/retrosternal goiter) 0 (0.0) 0 (0.0) 7 (1.5) 0 (0.0) 0 (0.0) 4 (3.2) Cosmetic indication 384 (44.3) 412 (29.1) 2 (0.4) 31 (20.0) 99 (37.5) 2 (1.6) Histological follow-up Benign multinodular goiter 759 (76.3) 1,281 (81.0) 433 (76.1) 131 (73.6) 236 (82.8) 105 (76.1) Thyroiditis 36 (3.6) 50 (3.2) 20 (3.5) 7 (3.9) 3 (1.1) 2 (1.5) Follicular carcinoma 7 (0.7) 5 (0.3) 5 (0.9) 0 (0.0) 1 (0.4) 7 (5.1) Papillary carcinoma 76 (7.6) 96 (6.1) 44 (7.7) 9 (5.1) 18 (6.3) 4 (2.9) Medullary carcinoma 2 (0.2) 2 (0.1) 3 (0.5) 2 (1.1) 1 (0.4) 0 (0.0) Undifferentiated thyroid cancer 0 (0.0) 1 (0.1) 6 (1.1) 0 (0.0) 1 (0.4) 1 (0.7) Secondary malignant tumor 0 (0.0) 1 (0.1) 2 (0.4) 0 (0.0) 0 (0.0) 1 (0.7) Lymphoma 0 (0.0) 2 (0.1) 6 (1.1) 0 (0.0) 1 (0.4) 0 (0.0) Squamous cell carcinoma 0 (0.0) 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) Adenoma 115 (11.6) 142 (9.0) 47 (8.3) 29 (16.3) 24 (8.4) 18 (13.0) Abscess 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Final diagnosis Benign 910 (91.5) 1,474 (93.1) 501 (88.1) 167 (93.8) 263 (92.3) 125 (90.6) 0.561 Malignant 85 (8.5) 110 (6.9) 68 (11.9) 11 (6.2) 22 (7.7) 13 (9.4) Recurrent goiter No 995 (100.0) 1,572 (99.2) 472 (83.0) 178 (100.0) 285 (100.0) 130 (94.2) Yes 0 (0.0) 12 (0.8) 97 (17.0) 0 (0.0) 0 (0.0) 8 (5.8)
TBSRTC: The Bethesda System for Reporting Thyroid Cytology, Second Edition 2010 Bethesda, Maryland; AUS: atypia of undetermined significance; FLUS: follicular lesion of undetermined significance; significant.